Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting Bluejay Diagnostics (NASDAQ: BJDX) announced an abstract acceptance for the 2026 SAEM Annual Meeting, May 18–21, 2026 in Atlanta.The presentation reports SYMON-I pilot results linking emergency department IL-6 levels to organ dysfunction (SOFA) over the first three hospital days and notes the ongoing SYMON-II validation study.

#BJDX Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

www.stocktitan.net/news/BJDX/bluejay-announ...

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent

#BJDX Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

www.stocktitan.net/news/BJDX/bluejay-diagno...

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split effective at 12:01 a.m. ET on January 29, 2026. At the effective time every four issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 2,834,133 shares to approximately 708,533. The company’s trading symbol BJDX remains unchanged and a new CUSIP 095633608 will be used post-split. Prefunded warrants will be adjusted from 1,055,000 to 263,750. No fractional shares will be issued; holders will receive a cash payment in lieu of fractional shares. Transfer agent Continental Stock Transfer & Trust Company will act as exchange agent and certificate holders will receive instructions. Equity awards and warrants will be proportionally adjusted.The company noted it does not yet have FDA clearance for its Symphony System; its IL-6 sepsis test is designed for ~20-minute sample-to-result performance.

#BJDX Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

www.stocktitan.net/news/BJDX/bluejay-diagno...

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production Bluejay Diagnostics (NASDAQ: BJDX) announced completion of commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6) for its Symphony™ cartridge program on December 29, 2025. The company said both antibody types met internal performance criteria for reactivity and intended diagnostic use based on internal testing.Bluejay reported production using third-party and proprietary immunogens, plans to use its proprietary immunogen for ongoing development and IP strategy, and estimates current inventory can support production of more than nine million Symphony cartridges, with capability to produce additional antibodies as needed. Symphony remains under development and subject to further validation and regulatory review.

#BJDX Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

www.stocktitan.net/news/BJDX/bluejay-diagno...

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships Bluejay Diagnostics (NASDAQ:BJDX) reported Q3 2025 results and highlighted clinical and financing progress.Key facts: SYMON-II pivotal trial is ~50% enrolled and aims to validate IL-6 predictive performance for 28-day mortality; Symphony sample testing is planned by late 2026 and a potential FDA 510(k) submission is targeted in 2027, subject to financing. The company completed a $4.5M PIPE in October and a $3.85M warrant-inducement in April; cash was $3.08M and stockholders’ equity $3.69M as of Sept 30, 2025. Bluejay amended supply agreements with SanyoSeiko and says Symphony delivers results in ~20 minutes.

#BJDX Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

www.stocktitan.net/news/BJDX/bluejay-diagno...

🚀 Exciting times for #BJDX! With a strong upward momentum, it's trading at $3.38, well above its 10-day SMA & 20-day EMA. Despite being overbought, the positive MACD suggests more gains ahead. Targeting $3.60 & $3.80 with a stop at $3.20. Stay sharp, traders! 📈 #FeetrAI

🚀 Exciting times for #BJDX! With a breakthrough in AI diagnostics and a strategic healthcare partnership, this stock is on fire! 🔥 Trading at $3.46, well above its 10-day SMA, it's showing strong bullish momentum. Consider a long position targeting $3.80-$4.00! 📈 #Innovation #Healthcare

🚀 Exciting times for #BJDX! With a current price of $3.46, it's soaring above its 10-day SMA, signaling strong bullish vibes. High RSI suggests overbought, but positive MACD and spiking volumes hint at more gains. Consider a long position with targets at $3.70 & $4.00. 📈 #FeetrAI

🚀 Exciting times for #BJDX! Trading at $3.46 with strong momentum and a 14-day RSI of 75.32, this stock is on the move! 📈 Bullish MACD signals and volume spikes suggest potential gains. Consider a long position targeting $3.80-$4.00, but stay alert to market trends! #FeetrAI

#BJDX looking okay. smaller size as I think market is quite bearish in the short term

🚀 Exciting times for #BJDX! Trading at $2.75 with bullish momentum, RSI near 69, and a positive MACD. Consider a LONG entry at $2.70, targeting $3.00 & $3.20. Stop loss at $2.50. Speculative play with moderate confidence—watch for news! 📈 #FeetrAI #StockMarket

🚀 Exciting times for #BJDX! Trading at $3.02, this stock is on a bullish run with RSI near 70 and MACD showing upward momentum. With the 10-day SMA & 8-day EMA below current price, consider a LONG position targeting $3.50-$3.80. 📈 #FeetrAI #StockMarket #BullishTrend

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules Bluejay Diagnostics (NASDAQ: BJDX) announced a private placement to raise approximately $4.5 million by selling 2,250,000 shares (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares at a $2.00 purchase price and accompanying warrants. The Series F warrants carry a $1.75 exercise price, are exercisable immediately and expire 5.5 years after issuance. The offering is priced at-the-market under Nasdaq rules, is expected to close on or about October 10, 2025, and is being placed exclusively by Rodman and Renshaw. Net proceeds are intended to fund FDA approval efforts (including clinical studies), R&D, and general working capital. Securities will be issued under applicable exemptions and subject to resale registration rights.

#BJDX Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/BJDX/bluejay-diagno...

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), a medical diagnostics company focused on developing rapid near-patient testing solutions for critical care, today announced that it has entered into an Agreement to Amend the

#BJDX Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

www.stocktitan.net/news/BJDX/bluejay-diagno...

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update Bluejay Diagnostics (NASDAQ: BJDX) has reported its Q2 2025 business update, highlighting progress in its Symphony IL-6 test program. The company has initiated the SYMON-II pivotal clinical trial to validate findings from the successful SYMON-I pilot study, with completion expected by end of 2026 and FDA 510(k) submission targeted for 2027.Key developments include a manufacturing partnership with SanyoSeiko Co. for the Symphony analyzer and an amended agreement with Toray Industries extending cartridge manufacturing timeline to October 2026. The company raised $3.85 million through warrant inducement financing in April 2025 but anticipates requiring additional capital through 2027 for manufacturing, clinical trials, and regulatory activities.

#BJDX Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

www.stocktitan.net/news/BJDX/bluejay-diagno...

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update Bluejay Diagnostics (NASDAQ: BJDX) provided a mid-year update highlighting progress in its SYMON clinical program for sepsis detection. The company has initiated the SYMON-II pivotal study following successful SYMON-I pilot results, which showed IL-6 levels' potential to predict sepsis mortality. Bluejay aims for FDA 510(k) submission of its Symphony IL-6 test by Q4 2027, targeting approval by Q3 2028. The company faces financial challenges with $5.7M cash on hand, recent losses of $7.7M in 2024, and needs to raise $30M through 2027. Cost-saving measures include reducing headcount to 5 employees. A reverse stock split is proposed to maintain Nasdaq listing compliance. Manufacturing challenges persist as Bluejay explores outsourcing cartridge redevelopment while maintaining collaboration with SanyoSeiko for analyzer production.

#BJDX Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

www.stocktitan.net/news/BJDX/bluejay-diagno...

🚨 FeetrAI Alert: #BJDX is trading at $2.36, below key moving averages with bearish momentum. RSI hints at oversold levels, but MACD stays negative. Low volume signals caution. Short entry at $2.40, targets $2.20 & $2.00, stop loss at $2.60. Stay sharp for news! 📉📈

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings - Bluejay Diagnostics (NASDAQ:BJDX), CVRx (NASDAQ:CVRX)

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings read more

www.benzinga.com/25/04/44696357/nasdaq-su...

#BJDX #CVRX #CYCU #Earnings #Equities #Mid #Day #Market #Update #News #NEXT

Event Attributes

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Apr 7th - #ACHR #SOUN #JBLU #CLSK #EQX #RXRX #JNVR #CIFR #RIOT #WOLF #BTCS #QBTS #RGTI #SGHC #SMR #WINT #BJDX #WULF #BBAI #CLF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Bluejay Diagnostics Raises Fresh $3.7M Capital: New Warrant Deal Strengthens Balance Sheet Strategic warrant transaction brings immediate $3.7M to Bluejay Diagnostics, with potential for additional funding through new warrant issuance. See deal implications.

#BJDX Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

www.stocktitan.net/news/BJDX/bluejay-diagno...

#ORIS #RKDA #TARA #PRFX #BJDX #FOXX all did very well today, each with HUGE StockQuakes level.

#investing #trading #stocks #AI

See stockquakes.substack.com for more info.

#BJDX Bluejay Diagnostics Announces Reverse Stock Split

www.stocktitan.net/news/BJDX/bluejay-diagno...